Literature DB >> 16329193

Clinical and laboratory parameters that define clinically relevant B-CLL subgroups.

N Chiorazzi1, S L Allen, M Ferrarini.   

Abstract

B cell-type chronic lymphocytic leukemia (B-CLL) is a heterogeneous disease. This is reflected by the very wide-ranging clinical courses that B-CLL patients experience and by the marked variation in laboratory findings between patients. In this chapter, we will review the various clinical and laboratory parameters that divide B-CLL patients into "subgroups," and correlate the parameters that define them. When feasible, we will also link clinical features to the cellular and genetic characteristics recently defined for these leukemic cells. The discussion is limited to parameters that define phenotypes or subgroups that may relate to disease activity and clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16329193     DOI: 10.1007/3-540-29933-5_7

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  3 in total

1.  The CD38 ectoenzyme family: advances in basic science and clinical practice.

Authors:  Fortunato Morabito; Rajendra N Damle; Silvia Deaglio; Michael Keating; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

2.  Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Authors:  Elizabeth S Raveche; Erica Salerno; Brian J Scaglione; Vijaya Manohar; Fatima Abbasi; Yi-Chu Lin; Torgny Fredrickson; Pablo Landgraf; Sumant Ramachandra; Konrad Huppi; Jorge R Toro; Vincent E Zenger; Robert A Metcalf; Gerald E Marti
Journal:  Blood       Date:  2007-03-09       Impact factor: 22.113

3.  Myc roles in hematopoiesis and leukemia.

Authors:  M Dolores Delgado; Javier León
Journal:  Genes Cancer       Date:  2010-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.